We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.66 | -2.34% | 27.50 | 28.49 | 27.40 | 28.31 | 65,491,402 | 00:39:06 |
From May 2019 to May 2024
By Adam Clark
The European Union is planning to purchase up to 300 million additional doses of the Covid-19 vaccine produced by Pfizer Inc. and BioNTech SE, its executive body said Friday.
The European Commission said it was proposing to the EU's member states the purchase of an additional 200 million doses with an option for another 100 million doses. The doses would be delivered from the second quarter of 2021.
This would bring the EU's potential purchases of the vaccine, the first to be approved and used within the bloc, to 600 million doses in total. The EU has secured up to 2.3 billion doses of a variety of vaccine candidates.
A vaccine produced by Moderna Inc. was authorized within the EU on Wednesday and other vaccines are expected to be approved soon, the European Commission said.
Write to Adam Clark at adam.clark@wsj.com
(END) Dow Jones Newswires
January 08, 2021 05:17 ET (10:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
